Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Cited by (1,078)

Items 601–700 of 1,078

1. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy
   Ninh My La-Beck, Gary W. Jean, Cindy Huynh, Saeed K Alzghari, Devin B. Lowe · 2015 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
2. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
   Sarah Joanne Welsh, Helen Rizos, Richard A. Scolyer, Georgina Venetia Long · 2016 · European Journal of Cancer
3. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis
   Daniel Y. Wang, Fei Ye, Shilin Zhao, Douglas Buckner Johnson · 2017 · OncoImmunology
4. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study
   Luana Calabrò, Aldo Morra, Diana Giannarelli, Giovanni Amato, Armida D’Incecco, Alessia Covre, Arthur R. Lewis, Marlon Cezar Rebelatto, Riccardo Danielli, Maresa Altomonte et al. · 2018 · The Lancet Respiratory Medicine
5. Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi‐institutional retrospective study
   Yasuhiro Nakamura, Ryota Tanaka, Yuri Asami, Yukiko Teramoto, Taichi Imamura, Sayuri Sato, Hiroshi Maruyama, Yasuhiro Fujisawa, Taisuke Matsuya, Manabu Fujimoto et al. · 2016 · The Journal of Dermatology
6. Hepatocellular carcinoma in the era of immunotherapy
   Hao‐Wen Sim, Jennifer Jane Knox · 2017 · Current Problems in Cancer
7. Temozolomide-associated hypermutation in gliomas
   Serah Choi, Yao Yu, Matthew Grimmer, Michael Traut Wahl, Susan Marina Chang, J Costello · 2018 · Neuro-Oncology
8. TGF-β in T Cell Biology: Implications for Cancer Immunotherapy
   Amina Dahmani, Jean‐Sébastien Delisle · 2018 · Cancers
9. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study
   Abu-Sbeih, Hamzah, Ali, Faisal S., Alsaadi, Dana, Jennings, Joseph, Luo, Wenyi, Gong, Zimu, Richards, David M., Charabaty, Aline, Wang, Yinghong · 2018 · Journal for ImmunoTherapy of Cancer
10. Regulatory T cells: a potential target in cancer immunotherapy
    Kohei Shitara, Hiroyoshi Nishikawa · 2018 · Annals of the New York Academy of Sciences
11. Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T
    Dok Hyun Yoon, Mark J. Osborn, Jakub Tolar, Chong Kim · 2018 · International Journal of Molecular Sciences
12. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019
    Claus Garbe, Teresa Maria Santos Amaral, Ketty Peris, Axel Hauschild, Petr Arenberger, Lars Bastholt, Veronique A. Bataille, V. del Mármol, Brigitte Dréno, Maria Concetta Fargnoli et al. · 2019 · European Journal of Cancer
13. Rational Cancer Treatment Combinations: An Urgent Clinical Need
    Julia Boshuizen, Daniel S. Peeper · 2020 · Molecular Cell
14. The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies
    Amin Daei Sorkhabi, Leila Mohamed Khosroshahi, Aila Sarkesh, Amirhossein Mardi, Ali Aghebati‐Maleki, Leili Aghebati Maleki, Behzad Baradaran · 2023 · Frontiers in Immunology
15. Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
    Xiangyu Gao, Nong Xu, Ziyu Li, Lin Shen, Ke Ji, Zhong Zheng, Dan Liu, Hanmei Lou, Li Bai, Tianshu Liu et al. · 2023 · The Lancet Oncology
16. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery
    Jack M. Qian, James B. Yu, Harriet M. Kluger, Veronica Chiang · 2016 · Cancer
17. Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond
    Kristina Buder‐Bakhaya, Jessica C. Hassel · 2018 · Frontiers in Immunology
18. Targeted Intracellular Delivery of Antibodies: The State of the Art
    Tatiana A. Slastnikova, Alexey V. Ulasov, Andrey A. Rosenkranz, Alexander S. Sobolev · 2018 · Frontiers in Pharmacology
19. USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer
    Dongni Shi, Xianqiu Wu, Yunting Jian, Junye Wang, Chengmei Huang, Shuang Mo, Yue Li, Fengtian Li, Chao Zhang, Dongsheng Zhang et al. · 2022 · Nature Communications
20. Melanoma subtypes demonstrate distinct PD-L1 expression profiles
    Genevieve J. Kaunitz, Tricia R. Cottrell, Mohammed T. Lilo, Valliammai Muthappan, Jessica Esandrio, Sneha Berry, Haiying Xu, Aleksandra Ogurtsova, Robert A. Anders, Alexander H. Fischer et al. · 2017 · Laboratory Investigation
21. Checkpoint inhibitors in triple‐negative breast cancer (TNBC): Where to go from here
    Maryann J. Kwa, Sylvia Adams · 2018 · Cancer
22. Principles of adoptive T cell therapy in cancer
    Özcan Met, Kasper Mølgaard, Christopher Aled Chamberlain, Marco Donia, Inge Marie Svane · 2018 · Seminars in Immunopathology
23. Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer
    Michael Roderick Cook, Chul Kim · 2019 · JAMA Oncology
24. Current Perspectives on Nasopharyngeal Carcinoma
    Hui Mei Lee, Kazuhide S. Okuda, Fermín Eduardo González, Vyomesh Patel · 2019 · Advances in experimental medicine and biology
25. Inflammatory Mechanisms of HCC Development
    Maria Grazia Refolo, Caterina Messa, Vito Guerra, Brian Irving Carr, Rosalba D’Alessandro · 2020 · Cancers
26. Immune Checkpoint Blockade in Cancer Therapy
    James Patrick Allison · 2015 · JAMA
27. A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
    Julie Westerlin Kjeldsen, Cathrine Lund Lorentzen, Evelina Martinenaite, Eva Ellebæk, Marco Donia, Rikke Boedker Holmstroem, Tobias Wirenfeldt Klausen, Cecilie Oelvang Madsen, Shamaila Munir Ahmed, Stine Emilie Weis-Banke et al. · 2021 · Nature Medicine
28. Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
    Don Steven Dizon, Lada Krilov, Ezra E.W. Cohen, Tara C. Gangadhar, Patricia A. Ganz, Thomas A. Hensing, Stephen P. Hunger, Smitha Krishnamurthi, Andrew B. Lassman, Merry Jennifer Markham et al. · 2016 · Journal of Clinical Oncology
29. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy
    Binghao Zhao, Huanzhang Li, Yu Xia, Yaning Wang, Yuekun Wang, Yixin Shi, Hao Xing, Tian Qu, Yu Wang, Wenbin Ma · 2022 · Journal of Hematology & Oncology
30. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)
    Sibylle C. Mellinghoff, Jens Panse, Nael Alakel, Gerhard Behre, Dieter Buchheidt, Maximilian Christopeit, Justin Hasenkamp, Michael G Kiehl, Michael Koldehoff, Stefan W. Krause et al. · 2017 · Annals of Hematology
31. Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment
    Peijie Wu, Wei Qiang Gao, Miao Su, Edouard Collins Nice, Wenhui Zhang, Jie Lin, Na Xie · 2021 · Frontiers in Cell and Developmental Biology
32. Interferon-Gamma–Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor–Colitis
    Sarah Christina Sasson, Stephanie M. Slevin, Vincent Cheung, Isar Nassiri, Anna Claire Olsson-Brown, Eve Fryer, Ricardo C. Ferreira, Dominik Trzupek, Tarun Gupta, Lulia Al‐Hillawi et al. · 2021 · Gastroenterology
33. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents
    Daniel L. Suzman, Lorraine Cheryl Pelosof, Amy S. Rosenberg, Mark Avigan · 2018 · Liver International
34. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study
    Andrea Forschner, Florian Battke, Dirk Hadaschik, Martin Schulze, Stephanie Weißgraeber, Tina Han, Maria Kopp, Maximilian Frick, Bernhard Daniel Klumpp, Nicola Tietze et al. · 2019 · Journal for ImmunoTherapy of Cancer
35. Immune checkpoint inhibitors: The linchpins of modern immunotherapy
    Breelyn Ann Wilky · 2019 · Immunological Reviews
36. Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms
    Johannes Hofland, Gregory Kaltsas, Wouter W. de Herder · 2019 · Endocrine Reviews
37. PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
    Claud M. Grigg, Naiyer A. Rizvi · 2016 · Journal for ImmunoTherapy of Cancer
38. The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment
    Jason B. Williams, Brendan L. Horton, Yan Zheng, Yukan Duan, Jonathan D. Powell, Thomas Frank Gajewski · 2017 · The Journal of Experimental Medicine
39. Anti–PD-1/anti–CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8 + T cell trafficking
    David Taggart, Tereza Andreou, Karen J. Scott, Jennifer M. Williams, Nora Rippaus, Rebecca J. Brownlie, Elizabeth J. Ilett, Robert J. Salmond, Alan A. Melcher, Mihaela Lorger · 2018 · Proceedings of the National Academy of Sciences
40. Bispecific antibodies in cancer immunotherapy
    Eva Dahlén, Niina Veitonmäki, Per Norlén · 2018 · Therapeutic Advances in Vaccines and Immunotherapy
41. The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution
    Ajit J. Nirmal, Zoltan Maliga, Tuulia Vallius, Brian Quattrochi, Alyce A. Chen, Connor A. Jacobson, Roxanne J. Pelletier, Clarence Yapp, Raquel Arias-Camison, Yu‐An Chen et al. · 2022 · Cancer Discovery
42. Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors
    Elkrief, Arielle, El Raichani, Layal, Richard, Corentin, Messaoudene, Meriem, Belkaid, Wiam, Malo, Julie, Belanger, Karl, Miller, Wilson, Jamal, Rahima, Letarte, Nathalie et al. · 2019 · OncoImmunology
43. Current Perspectives in Cancer Immunotherapy
    Theodoulakis Christofi, Stavroula Baritaki, Luca Falzone, Massimo Libra, Apostolos Zaravinos · 2019 · Cancers
44. Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action
    Zena N. Willsmore, Ben G T Coumbe, Silvia Crescioli, Sara Reci, Ayushi Gupta, R. J. C. Harris, Alicia M. Chenoweth, Jitesh Chauhan, Heather J. Bax, Alexandra J. McCraw et al. · 2021 · European Journal of Immunology
45. Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials
    Badi Edmond El Osta, Fangyuan Hu, Reem Ahmed Sadek, Rohini Chintalapally, Shou Ching Tang · 2017 · Critical Reviews in Oncology/Hematology
46. Small‐Molecule Prodrug Nanoassemblies: An Emerging Nanoplatform for Anticancer Drug Delivery
    Guanting Li, Bingjun Sun, Yaqiao Li, Cong Luo, Zhonggui He, Jin Sun · 2021 · Small
47. Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
    Aleksandar Obradovic, Diana K. Graves, Michael J. Korrer, Yu Wang, Sohini Roy, Abdullah Naveed, Yaomin Xu, Adam Luginbuhl, Joseph Curry, Michael K. Gibson et al. · 2022 · Clinical Cancer Research
48. Managing Metastatic Melanoma in 2022: A Clinical Review
    Benjamin Switzer, Igor Puzanov, Joseph J. Skitzki, Lamya Hamad, Marc S. Ernstoff · 2022 · JCO Oncology Practice
49. Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma
    Xingliang Guo, Hua Jiang, Bizhi Shi, Min Zhou, Honghong Zhang, Zhimin Shi, Guoxiu Du, Hong Luo, Xiuqi Wu, Yi Wang et al. · 2018 · Frontiers in Pharmacology
50. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
    James Larkin, Michele Del Vecchio, Mario Mandalà, Helen J Gogas, Ana Maria Arance, Stéphane Dalle, Charles Lance Cowey, Michael Schenker, Jean‐Jacques Grob, Vanna Chiarion‐Sileni et al. · 2023 · Clinical Cancer Research
51. Integrative Approaches to Cancer Immunotherapy
    Gregory Lee Szeto, Stacey D. Finley · 2019 · Trends in cancer
52. A gene expression signature of TREM2hi macrophages and γδ T cells predicts immunotherapy response
    Donghai Xiong, Yian Wang, Ming You · 2020 · Nature Communications
53. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
    Ralf Gutzmer, Anika Koop, Friedegund Elke Meier, Jessica C. Hassel, Patrick Andres Maximilian Terheyden, Lisa Zimmer, Lucie Heinzerling, Selma Ugurel, Claudia Pföhler, Anja Gesierich et al. · 2017 · European Journal of Cancer
54. Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study
    Kobayashi, Tomoko, Iwama, Shintaro, Yasuda, Yoshinori, Okada, Norio, Tsunekawa, Taku, Onoue, Takeshi, Takagi, Hiroshi, Hagiwara, Daisuke, Ito, Yoshihiro, Morishita, Yoshiaki et al. · 2018 · Journal of the Endocrine Society
55. IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma
    Erik Ladomersky, Lijie Zhai, Alicia C. Lenzen, Kristen L. Lauing, Jun Qian, Denise M. Scholtens, Galina Gritsina, Xuebing Sun, Ye Liu, Fenglong Yu et al. · 2018 · Clinical Cancer Research
56. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma
    Indini, Alice, Di Guardo, Lorenza, Cimminiello, Carolina, Prisciandaro, Michele, Randon, Giovanni, De Braud, Filippo, Del Vecchio, Michele · 2019 · Journal of Cancer Research and Clinical Oncology
57. Current progress in immunotherapy for pancreatic cancer
    Kelly Foley, Victoria Kim, Elizabeth M. Jaffee, Lei Zheng · 2015 · Cancer Letters
58. T cell exhaustion: from pathophysiological basics to tumor immunotherapy
    Kemal Catakovic, Eckhard Klieser, Daniel Neureiter, Roland Geisberger · 2017 · Cell Communication and Signaling
59. Overview of current targeted therapy in gallbladder cancer
    Xiaoling Song, Yunping Hu, Yongsheng Li, Rong Shao, Fatao Liu, Yingbin Liu · 2020 · Signal Transduction and Targeted Therapy
60. Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade
    Valpione, Sara, Pasquali, Sandro, Campana, Luca Giovanni, Piccin, Luisa, Mocellin, Simone, Pigozzo, Jacopo, Chiarion-Sileni, Vanna · 2018 · Journal of Translational Medicine
61. Neurological toxicities associated with immune-checkpoint inhibitors
    Mehdi Touat, Daniel Talmasov, Damien Ricard, Dimitri Psimaras · 2017 · Current Opinion in Neurology
62. Immunotherapy for glioblastoma: the promise of combination strategies
    Mathilde Bausart, Véronique Préat A, Alessio Malfanti · 2022 · Journal of Experimental & Clinical Cancer Research
63. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation
    Giuseppe Valentino Masucci, Alessandra Cesano, Rachael Elizabeth Hawtin, Sylvia Janetzki, Jenny Zhang, Ilan Richard Kirsch, Kevin K. Dobbin, John David Alvarez, Paul B. Robbins, Senthamil R. Selvan et al. · 2016 · Journal for ImmunoTherapy of Cancer
64. Association of Time‐Varying Clearance of Nivolumab With Disease Dynamics and Its Implications on Exposure Response Analysis
    C Liu, J Yu, H Li, J Liu, Yuan Xu, P Song, Q Liu, Hong Zhao, J Xu, VE Maher et al. · 2017 · Clinical Pharmacology & Therapeutics
65. Immunoregulatory functions of VISTA
    Elizabeth C. Nowak, Janet Louise Lines, Frederick S. Varn, Jie Deng, Aurélien Sarde, Rodwell Mabaera, Anna Kuta, Isabelle Le Mercier, Chao Cheng, Randolph J. Noelle · 2017 · Immunological Reviews
66. TIGIT: a novel immunotherapy target moving from bench to bedside
    Benjamin Lev Solomon, Ignacio Garrido‐Laguna · 2018 · Cancer Immunology Immunotherapy
67. Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
    Paul M Hofman, Simon Heeke, Catherine Alix‐Panabières, Klaus Pantel · 2019 · Annals of Oncology
68. Immune-based therapies for hepatocellular carcinoma
    David James Pinato, Nadia Guerra, Petros Fessas, Ravindhi Murphy, Takashi Mineo, Francesco Angelo Mauri, Sujit K. Mukherjee, Mark R. Thursz, Ching Ngar Wong, Rohini Sharma et al. · 2020 · Oncogene
69. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies
    Elísabeth Pérez-Ruiz, Ignacio Melero, Joanna Kopecka, Ana Bela Sarmento‐Ribeiro, Marilina García‐Aranda, Javier De Las Rivas · 2020 · Drug Resistance Updates
70. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition
    Markus Vincent Heppt, Lucie Heinzerling, Katharina Charlotte Kähler, Andrea Forschner, Michael Constantin Kirchberger, Carmen Loquai, Markus Meißner, Friedegund Elke Meier, Patrick Andres Maximilian Terheyden, Beatrice Schell et al. · 2017 · European Journal of Cancer
71. Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells
    Dhifaf Sarhan, Frank M. Cichocki, Bin Zhang, Ashley M. Yingst, Stephen R. Spellman, Sarah Cooley, Michael R. Verneris, Bruce R. Blazar, Jeffrey S. Miller · 2016 · Cancer Research
72. Phosphatidylserine: A cancer cell targeting biomarker
    Bhupender Sharma, Shamsher S. Kanwar · 2017 · Seminars in Cancer Biology
73. Role of PD-1 in Immunity and Diseases
    Kenji Chamoto, Muna Al-Habsi, Tasuku Honjo · 2017 · Current topics in microbiology and immunology
74. Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences
    Nikko Brix, Anna Tiefenthaller, Heike Anders, Claus Belka, Kirsten Lauber · 2017 · Immunological Reviews
75. Immunomodulators targeting the PD‐1/PD‐L1 protein‐protein interaction: From antibodies to small molecules
    Jeffrey Yang, Longqin Hu · 2018 · Medicinal Research Reviews
76. Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy
    Pingsheng Huang, Xiaoli Wang, Xiaoyu Liang, Jing Yang, Chuangnian Zhang, Deling Kong, Weiwei Wang · 2018 · Acta Biomaterialia
77. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
    Xi Chen, Xiaohui Pan, Wenxin Zhang, Hongjie Guo, Shuyuan Cheng, Qiaojun He, Bo Yang, Ling Ding · 2019 · Acta Pharmaceutica Sinica B
78. Metabolism in tumor microenvironment: Implications for cancer immunotherapy
    Rongchen Shi, Yi‐Quan Tang, Hongming Miao · 2020 · MedComm
79. Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity
    Xinghua Pang, Zhaoliang Huang, Tingting Zhong, Peng Zhang, Zhongmin Maxwell Wang, Michelle Xia, Baiyong Li · 2023 · mAbs
80. A Dual Immunotherapy Nanoparticle Improves T‐Cell Activation and Cancer Immunotherapy
    Yu Mi, Christof C. Smith, Feifei Yang, Yanfei Qi, Kyle C. Roche, Jonathan Stuart Serody, Benjamin Garrett Vincent, Andrew Zhuang Wang · 2018 · Advanced Materials
81. Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis
    Sandhya Manohar, Panagiotis Kompotiatis, Charat Thongprayoon, Wisit Cheungpasitporn, Joerg Herrmann, Sandra M. Herrmann · 2018 · Nephrology Dialysis Transplantation
82. Engineering Dendritic-Cell-Based Vaccines and PD-1 Blockade in Self-Assembled Peptide Nanofibrous Hydrogel to Amplify Antitumor T-Cell Immunity
    Pengxiang Yang, Huijuan Song, Yibo Qin, Pingsheng Huang, Chuangnian Zhang, Deling Kong, Weiwei Wang · 2018 · Nano Letters
83. Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer
    Teo, Zhi Ling, Versaci, Stephanie, Dushyanthen, Sathana, Caramia, Franco, Savas, Peter, Mintoff, Chris P., Zethoven, Magnus, Virassamy, Balaji, Luen, Stephen J., McArthur, Grant A. et al. · 2017 · Cancer Research
84. Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators
    Isabelle Le Mercier, Janet Louise Lines, Randolph J. Noelle · 2015 · Frontiers in Immunology
85. Predictors of responses to immune checkpoint blockade in advanced melanoma
    Nicolas Jacquelot, María P. Roberti, David Pierre Enot, Sylvie Rusakiewicz, Nils Ternès, S. Jegou, David Michael Woods, Andressa L. Sodré, Morten Hansen, Yaron Meirow et al. · 2017 · Nature Communications
86. Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials
    Jackson G. Egen, Wenjun Ouyang, Lawren C. Wu · 2020 · Immunity
87. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
    Anas Younes, Joshua Brody, Cecilia del Carmen Carpio, Armando López‐Guillermo, Dina Ben‐Yehuda, Burhan Ferhanoğlu, Arnon Nagler, Muhıt Özcan, Irit Mazza Avivi, Francesc Bosch et al. · 2019 · The Lancet Haematology
88. A comprehensive review of immune checkpoint inhibitors for cancer treatment
    Md Aslam Hossain · 2024 · International Immunopharmacology
89. Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials
    Masatoshi Kudo · 2017 · Oncology
90. Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma
    Allison Betof Warner, Ryan David Nipp, Anita Giobbie‐Hurder, Romany Anne Nilanthi Johnpulle, Krista M. Rubin, Samuel M. Rubinstein, Keith T. Flaherty, Donald P. Lawrence, Douglas Buckner Johnson, Ryan Joseph Sullivan · 2017 · The Oncologist
91. Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy
    Luc Cabel, Charlotte Proudhon, Emanuela Romano, Nicolas Girard, Olivier J Lantz, Marc‐Henri Stern, Jean‐Yves Pierga, François‐Clément Bidard · 2018 · Nature Reviews Clinical Oncology
92. Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance
    Young‐Jun Park, Da‐Sol Kuen, Yeonseok Chung · 2018 · Experimental & Molecular Medicine
93. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma
    Lisa Zimmer, Susmitha Apuri, Zeynep Eroglu, Lisa A. Kottschade, Andrea Forschner, Ralf Gutzmer, Max S. Schlaak, Lucie Heinzerling, Angela M. Krackhardt, Carmen Loquai et al. · 2017 · European Journal of Cancer
94. Immune checkpoint inhibitor‐induced Type 1 diabetes: a systematic review and meta‐analysis
    Halis Kaan Aktürk, Doga Kahramangil, Amara Sarwal, Lilian Hoffecker, Mohammad Hassan Murad, Aaron W. Michels · 2019 · Diabetic Medicine
95. Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up
    Joost H. van den Berg, Bianca Heemskerk, Nienke van Rooij, Raquel Gomez-Eerland, Samira Michels, Maaike van Zon, Renate de Boer, Noor A. M. Bakker, Annelies Jorritsma‐Smit, Marit M. van Buuren et al. · 2020 · Journal for ImmunoTherapy of Cancer
96. Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study
    David M. O’Malley, Maryna Neffa, Bradley J. Monk, Tamar Melkadze, Marilyn Huang, Anna Kryzhanivska, Iurie Bulat, Tarek M. Meniawy, Andrea Bagameri, Wenge Wang et al. · 2021 · Journal of Clinical Oncology
97. Myasthenic crisis and polymyositis induced by one dose of nivolumab
    Toshihiro Kimura, Satoshi Fukushima, Azusa Miyashita, Jun Aoi, Masatoshi Jinnin, Takayuki Kosaka, Yukio Ando, Masakazu Matsukawa, Hiroyuki Inoue, Kazuma Kiyotani et al. · 2016 · Cancer Science
98. Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade
    Shinsuke Nakao, Yukinori Arai, Mamoru Tasaki, Midori YAMASHITA, Ryuji Murakami, Tatsuya Kawase, Nobuaki Amino, Motomu Nakatake, Hajime Kurosaki, Masamichi Mori et al. · 2020 · Science Translational Medicine
99. Bispecific and multispecific antibodies in oncology: opportunities and challenges
    Maria-Elisabeth Goebeler, Gernot Stuhler, Ralf Christian Bargou · 2024 · Nature Reviews Clinical Oncology
100. Targeted antibody and cytokine cancer immunotherapies through collagen affinity
     Ishihara, Jun, Ishihara, Ako, Sasaki, Koichi, Lee, Steve Seung-Young, Williford, John-Michael, Yasui, Mariko, Abe, Hiroyuki, Potin, Lambert, Hosseinchi, Peyman, Fukunaga, Kazuto et al. · 2019 · Science Translational Medicine